Eli Lilly Reports Positive Phase 1b Heart-2 Results for VERVE-102 PCSK9 Therapy

Eli Lilly and Company (NYSE:LLY) announced on May 25 positive results from the Phase 1b Heart-2 study for VERVE-102, an investigational base-editing therapy designed to deactivate the PCSK9 gene in the liver. The trial showed that VERVE-102 successfully reduced PCSK9 levels by up to [percentage], boosting hopes for a new cholesterol-lowering treatment.

The Product

VERVE-102 is a base-editing therapy that targets the PCSK9 gene in the liver, a key regulator of LDL cholesterol. It works by permanently modifying the DNA of liver cells to disable PCSK9 production, potentially offering a long-term solution for cholesterol reduction.

Pricing and Availability

Eli Lilly has not yet disclosed pricing or commercial availability for VERVE-102, as the therapy is still in early clinical development. Further trials are needed to confirm safety and efficacy before regulatory approvals.

Competition

VERVE-102 faces competition from other PCSK9-targeting therapies, such as injectable PCSK9 inhibitors (e.g., Repatha from Amgen and Praluent from Sanofi/Regeneron) and other gene therapies. However, VERVE-102's base-editing approach may offer a durable effect with a single dose, giving it a competitive edge.

Potential Impact on the Company

If VERVE-102 succeeds in later trials and gains regulatory approval, it could represent a major opportunity for Eli Lilly in the cholesterol-lowering market, which exceeds $20 billion annually. It also strengthens the company's position in gene therapy and gene editing.